Neurocrine Biosciences
NBIX
125 hedge funds and large institutions have $1.05B invested in Neurocrine Biosciences in 2014 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 47 increasing their positions, 40 reducing their positions, and 13 closing their positions.
43% more call options, than puts
Call options by funds: $10M | Put options by funds: $7M
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
18% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 40
3% more funds holding
Funds holding: 121 → 125 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less capital invested
Capital invested by funds: $1.12B → $1.05B (-$77.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12.6M |
| 2 |
Millennium Management
New York
|
+$5.77M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$5.65M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$5.12M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$4.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$15.5M |
| 2 |
O
OrbiMed
New York
|
-$10.9M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$3.68M |
| 4 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
-$3.4M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$3.26M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Envestnet Asset Management
Chicago,
Illinois
| $1K | – | – | – |
|
127
JP Morgan Chase
New York
| – | -$2.26M | -140,449 | Closed |
|
128
Adage Capital Partners
Boston,
Massachusetts
| – | -$2.19M | -136,286 | Closed |
|
|
HCMT
129
Highland Capital Management (Texas)
Dallas,
Texas
| – | -$1.29M | -80,000 | Closed |
|
|
SB
130
Suntrust Banks
Atlanta,
Georgia
| – | -$1.11M | -68,757 | Closed |
|
|
3NC
131
300 North Capital
Pasadena,
California
| – | -$824K | -51,189 | Closed |
|
|
HI
132
HBK Investments
Dallas,
Texas
| – | -$749K | -46,500 | Closed |
|
|
DY
133
Dowling & Yahnke
San Diego,
California
| – | -$483K | -30,000 | Closed |
|
|
SCM
134
Sterling Capital Management
Charlotte,
North Carolina
| – | -$300K | -18,625 | Closed |
|
|
TC
135
TFS Capital
West Chester,
Pennsylvania
| – | -$163K | -10,131 | Closed |
|
|
BJ
136
BlackRock Japan
Tokyo,
Japan
| – | -$13K | -793 | Closed |
|
|
TRCT
137
Tower Research Capital (TRC)
New York
| – | -$10K | -618 | Closed |
|
138
Creative Planning
Overland Park,
Kansas
| – | -$8K | -500 | Closed |
|
139
M&T Bank
Buffalo,
New York
| – | -$1K | -61 | Closed |
|
NBIX Hedge Fund Activity: Q2 2014 in Review
125 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2014, worth a combined $1.05B — down 6.9% from $1.12B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new NBIX positions and 13 closed out — a net gain of 4 holders — while 47 added to existing stakes and 40 trimmed.
The largest buyer was Great Point Partners, adding an estimated $12.6M. The largest seller was RA Capital Management, cutting an estimated $15.5M.
- 125 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2014, up from 121 in Q1 2014.
- Funds reported $1.05B of Neurocrine Biosciences stock for Q2 2014, down 6.9% quarter-over-quarter.
- 17 funds opened new Neurocrine Biosciences positions in Q2 2014 and 13 closed out, a net change of +4 holders.
- The largest Neurocrine Biosciences buyer in Q2 2014 was Great Point Partners, an estimated $12.6M added.
- The largest Neurocrine Biosciences seller in Q2 2014 was RA Capital Management, an estimated $15.5M sold.
Based on aggregated 13F filings for Q2 2014.